drugset / Trial / NCT01433172
Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer
Phase 1/2
Completed
73 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bankhead-Coley Florida Biomedical Research Program · collabJames and Esther King Biomedical Research Program · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and bad) a tumor vaccine used in combination with GM.CD40L and CCL21 have on the patient and their cancer. We also want to find out if the vaccine and the drugs can boost the immune system of these patients and how their immune system reacts, both before and after the vaccine treatment.
Timeline
- Start
- 2012-03-26
- Primary completion
- 2016-01-31
- Completion
- 2019-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CCL21 | Protein / enzyme biologic | — | Intrathecal |
| Comparator | Pembrolizumab | Monoclonal antibody | 1.5e+07 cells | Intrathecal |